NCT01946789 2025-01-22A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid TumorsAltor BioSciencePhase 1 Completed26 enrolled 22 charts
NCT03853317 2024-08-09QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyImmunityBio, Inc.Phase 2 Terminated9 enrolled 13 charts
NCT02465957 2024-05-02QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)ImmunityBio, Inc.Phase 2 Terminated7 enrolled 11 charts